Investor Relations News Releases News Releases February 15, 2019 Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 Additional Formats PDF Version December 18, 2018 Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Additional Formats PDF Version December 4, 2018 Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 Additional Formats PDF Version November 19, 2018 RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. Additional Formats PDF Version November 14, 2018 RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version November 7, 2018 RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018 Additional Formats PDF Version November 6, 2018 RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 Additional Formats PDF Version October 3, 2018 RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering Additional Formats PDF Version October 1, 2018 RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering Additional Formats PDF Version September 26, 2018 RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference Additional Formats PDF Version August 28, 2018 RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Additional Formats PDF Version August 15, 2018 RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors Additional Formats PDF Version August 14, 2018 RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version August 7, 2018 RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 Additional Formats PDF Version August 2, 2018 RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan Additional Formats PDF Version August 1, 2018 RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring Additional Formats PDF Version June 28, 2018 BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury Additional Formats PDF Version May 18, 2018 RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts Additional Formats PDF Version May 11, 2018 RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors Additional Formats PDF Version May 10, 2018 RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version May 8, 2018 RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO Additional Formats PDF Version May 1, 2018 RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference Additional Formats PDF Version April 24, 2018 RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018 Additional Formats PDF Version April 16, 2018 RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma Additional Formats PDF Version April 11, 2018 RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering Additional Formats PDF Version April 9, 2018 RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version April 4, 2018 RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference Additional Formats PDF Version March 26, 2018 RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights Additional Formats PDF Version March 21, 2018 RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018 Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
Investor Relations News Releases News Releases February 15, 2019 Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 Additional Formats PDF Version December 18, 2018 Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Additional Formats PDF Version December 4, 2018 Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 Additional Formats PDF Version November 19, 2018 RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. Additional Formats PDF Version November 14, 2018 RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version November 7, 2018 RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018 Additional Formats PDF Version November 6, 2018 RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 Additional Formats PDF Version October 3, 2018 RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering Additional Formats PDF Version October 1, 2018 RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering Additional Formats PDF Version September 26, 2018 RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference Additional Formats PDF Version August 28, 2018 RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Additional Formats PDF Version August 15, 2018 RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors Additional Formats PDF Version August 14, 2018 RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version August 7, 2018 RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 Additional Formats PDF Version August 2, 2018 RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan Additional Formats PDF Version August 1, 2018 RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring Additional Formats PDF Version June 28, 2018 BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury Additional Formats PDF Version May 18, 2018 RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts Additional Formats PDF Version May 11, 2018 RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors Additional Formats PDF Version May 10, 2018 RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version May 8, 2018 RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO Additional Formats PDF Version May 1, 2018 RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference Additional Formats PDF Version April 24, 2018 RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018 Additional Formats PDF Version April 16, 2018 RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma Additional Formats PDF Version April 11, 2018 RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering Additional Formats PDF Version April 9, 2018 RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version April 4, 2018 RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference Additional Formats PDF Version March 26, 2018 RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights Additional Formats PDF Version March 21, 2018 RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018 Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
News Releases February 15, 2019 Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 Additional Formats PDF Version December 18, 2018 Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Additional Formats PDF Version December 4, 2018 Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 Additional Formats PDF Version November 19, 2018 RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. Additional Formats PDF Version November 14, 2018 RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version November 7, 2018 RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018 Additional Formats PDF Version November 6, 2018 RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 Additional Formats PDF Version October 3, 2018 RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering Additional Formats PDF Version October 1, 2018 RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering Additional Formats PDF Version September 26, 2018 RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference Additional Formats PDF Version August 28, 2018 RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Additional Formats PDF Version August 15, 2018 RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors Additional Formats PDF Version August 14, 2018 RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version August 7, 2018 RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 Additional Formats PDF Version August 2, 2018 RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan Additional Formats PDF Version August 1, 2018 RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring Additional Formats PDF Version June 28, 2018 BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury Additional Formats PDF Version May 18, 2018 RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts Additional Formats PDF Version May 11, 2018 RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors Additional Formats PDF Version May 10, 2018 RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version May 8, 2018 RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO Additional Formats PDF Version May 1, 2018 RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference Additional Formats PDF Version April 24, 2018 RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018 Additional Formats PDF Version April 16, 2018 RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma Additional Formats PDF Version April 11, 2018 RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering Additional Formats PDF Version April 9, 2018 RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version April 4, 2018 RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference Additional Formats PDF Version March 26, 2018 RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights Additional Formats PDF Version March 21, 2018 RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018 Additional Formats PDF Version
February 15, 2019 Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 Additional Formats PDF Version
December 18, 2018 Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Additional Formats PDF Version
December 4, 2018 Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 Additional Formats PDF Version
November 19, 2018 RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. Additional Formats PDF Version
November 14, 2018 RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version
November 7, 2018 RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018 Additional Formats PDF Version
November 6, 2018 RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 Additional Formats PDF Version
October 3, 2018 RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering Additional Formats PDF Version
October 1, 2018 RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering Additional Formats PDF Version
September 26, 2018 RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference Additional Formats PDF Version
August 28, 2018 RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Additional Formats PDF Version
August 15, 2018 RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors Additional Formats PDF Version
August 14, 2018 RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version
August 7, 2018 RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 Additional Formats PDF Version
August 2, 2018 RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan Additional Formats PDF Version
August 1, 2018 RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring Additional Formats PDF Version
June 28, 2018 BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury Additional Formats PDF Version
May 18, 2018 RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts Additional Formats PDF Version
May 11, 2018 RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors Additional Formats PDF Version
May 10, 2018 RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version
May 8, 2018 RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO Additional Formats PDF Version
May 1, 2018 RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference Additional Formats PDF Version
April 24, 2018 RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018 Additional Formats PDF Version
April 16, 2018 RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma Additional Formats PDF Version
April 11, 2018 RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering Additional Formats PDF Version
April 9, 2018 RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version
April 4, 2018 RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference Additional Formats PDF Version
March 26, 2018 RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights Additional Formats PDF Version
March 21, 2018 RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018 Additional Formats PDF Version
